Bridgeway Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-49,280
Closed -$808K – 1335
2026
Q2
$808K Hold
49,280
– – 0.01% 776
2026
Q1
$644K Hold
49,280
– – 0.01% 781
2025
Q4
$563K Buy
49,280
+7,700
+19% +$87.9K 0.01% 796
2025
Q3
$489K Buy
41,580
+22,380
+117% +$180K 0.01% 810
2025
Q2
$76.2K Buy
+19,200
New +$83.4K ﹤0.01% 1102

Other funds holding CTNM

Bridgeway Capital Management's CTNM Position: Q3 2026 in Review

Bridgeway Capital Management sold out of Contineum Therapeutics (CTNM) in Q3 2026, closing a stake of 49,280 shares — an estimated $808K sold.

Bridgeway Capital Management first reported a position in CTNM in Q2 2025 and held it in 5 quarters. The position peaked at $808K in Q2 2026. 118 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • Bridgeway Capital Management reported no remaining Contineum Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 49,280 Contineum Therapeutics shares in Q3 2026, an estimated $808K.
  • Bridgeway Capital Management first reported a position in Contineum Therapeutics in Q2 2025 and held it in 5 quarters.
  • Bridgeway Capital Management's Contineum Therapeutics position peaked at $808K in Q2 2026.
  • 118 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.